使用贝伐单抗治疗肝细胞癌的挑战：不良反应的发生率和缓解策略

IF 4 4区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Revista Espanola De Enfermedades Digestivas Pub Date : 2025-09-29 DOI:10.17235/reed.2025.11540/2025

Marta García-Calonge, Andrés Castaño-García, Ana María Piedra Cerezal, Helena González Sánchez, Daniel Muíño Domínguez, Manuel Rodríguez, Valentina Chiminazzo, María Varela Calvo

{"title":"使用贝伐单抗治疗肝细胞癌的挑战：不良反应的发生率和缓解策略","authors":"Marta García-Calonge, Andrés Castaño-García, Ana María Piedra Cerezal, Helena González Sánchez, Daniel Muíño Domínguez, Manuel Rodríguez, Valentina Chiminazzo, María Varela Calvo","doi":"10.17235/reed.2025.11540/2025","DOIUrl":null,"url":null,"abstract":"Recent systemic treatment advances have transformed hepatocellular carcinoma (HCC) management, particularly with immunotherapy's superior outcomes over tyrosine kinase inhibitors, as demonstrated in trials like HIMALAYA, CheckMate 9DW and Imbrave-150. Atezolizumab and bevacizumab (AtezoBev) are now standard first-line treatments for advanced HCC. However, they present a risk of adverse events (AEs) that require careful monitoring, especially in patients with advanced chronic liver disease and related complications. This study investigates bevacizumab-related complications (B-AEs) in this population, emphasizing the importance of rigorous patient selection and management in achieving successful outcomes.","PeriodicalId":21342,"journal":{"name":"Revista Espanola De Enfermedades Digestivas","volume":"118 ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.\",\"authors\":\"Marta García-Calonge, Andrés Castaño-García, Ana María Piedra Cerezal, Helena González Sánchez, Daniel Muíño Domínguez, Manuel Rodríguez, Valentina Chiminazzo, María Varela Calvo\",\"doi\":\"10.17235/reed.2025.11540/2025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent systemic treatment advances have transformed hepatocellular carcinoma (HCC) management, particularly with immunotherapy's superior outcomes over tyrosine kinase inhibitors, as demonstrated in trials like HIMALAYA, CheckMate 9DW and Imbrave-150. Atezolizumab and bevacizumab (AtezoBev) are now standard first-line treatments for advanced HCC. However, they present a risk of adverse events (AEs) that require careful monitoring, especially in patients with advanced chronic liver disease and related complications. This study investigates bevacizumab-related complications (B-AEs) in this population, emphasizing the importance of rigorous patient selection and management in achieving successful outcomes.\",\"PeriodicalId\":21342,\"journal\":{\"name\":\"Revista Espanola De Enfermedades Digestivas\",\"volume\":\"118 \",\"pages\":\"\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola De Enfermedades Digestivas\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17235/reed.2025.11540/2025\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Enfermedades Digestivas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17235/reed.2025.11540/2025","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

最近的全身治疗进展已经改变了肝细胞癌（HCC）的治疗，特别是免疫疗法比酪氨酸激酶抑制剂的效果更好，如HIMALAYA、CheckMate 9DW和Imbrave-150等试验所证明的那样。Atezolizumab和bevacizumab （AtezoBev）现在是晚期HCC的标准一线治疗。然而，它们存在不良事件（ae）的风险，需要仔细监测，特别是对于患有晚期慢性肝病和相关并发症的患者。本研究调查了该人群的贝伐单抗相关并发症（b- ae），强调了严格的患者选择和管理对取得成功结果的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Challenges of using bevacizumab for hepatocellular carcinoma: incidence of adverse effects and mitigation strategies.

Recent systemic treatment advances have transformed hepatocellular carcinoma (HCC) management, particularly with immunotherapy's superior outcomes over tyrosine kinase inhibitors, as demonstrated in trials like HIMALAYA, CheckMate 9DW and Imbrave-150. Atezolizumab and bevacizumab (AtezoBev) are now standard first-line treatments for advanced HCC. However, they present a risk of adverse events (AEs) that require careful monitoring, especially in patients with advanced chronic liver disease and related complications. This study investigates bevacizumab-related complications (B-AEs) in this population, emphasizing the importance of rigorous patient selection and management in achieving successful outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista Espanola De Enfermedades Digestivas 医学-胃肠肝病学

CiteScore

2.00

自引率

25.00%

发文量

400

审稿时长

6-12 weeks

期刊介绍： La Revista Española de Enfermedades Digestivas, Órgano Oficial de la Sociedad Española de Patología Digestiva (SEPD), Sociedad Española de Endoscopia Digestiva (SEED) y Asociación Española de Ecografía Digestiva (AEED), publica artículos originales, editoriales, revisiones, casos clínicos, cartas al director, imágenes en patología digestiva, y otros artículos especiales sobre todos los aspectos relativos a las enfermedades digestivas.